SuperworthNiagen Bioscience shares outstanding NAGE
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 82.5M
- On a year earlier
- −4.3%
- fewer shares
Niagen Bioscience had 82.5M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 4.3% fewer than a year earlier, so each share owns a little more of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 85.3M | +4% |
| FY2024 | 82.1M | +9% |
| FY2023 | 75.1M | +2% |
| FY2022 | 73.9M | +8% |
| FY2021 | 68.3M | +10% |
| FY2020 | 61.9M | +4% |
| FY2019 | 59.6M | +8% |
| FY2018 | 55.2M | +8% |
| FY2017 | 51.2M | +35% |
| FY2016 | 37.9M | +5% |
| FY2015 | 36.2M | +1% |
| FY2014 | 35.6M | +3% |
| FY2013 | 34.7M | +12% |
| FY2012 | 30.9M | +24% |
| FY2011 | 24.9M | +24% |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 82.5M | −4% | |
| Q1 FY26 | 84.6M | +2% | |
| Q4 FY25 | 85.3M | +4% | |
| Q3 FY25 | 86.6M | +11% | |
| Q2 FY25 | 86.2M | +14% | |
| Q1 FY25 | 83.2M | +11% | |
| Q4 FY24 | 82.1M | +9% | |
| Q3 FY24 | 77.8M | +4% | |
| Q2 FY24 | 75.6M | +1% | |
| Q1 FY24 | 75.2M | +1% | |
| Q4 FY23 | 75.1M | +2% | |
| Q3 FY23 | 75M | +10% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Niagen Bioscience
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.